GLP-1 medications can significantly reduce appetite and overall intake, making it harder to meet these demands
It is weekly, aimed squarely at obesity, and further along than brenipatide, with a plausible approval around 2027
ACS Omega 2 , 24992506, (2017)
For example, in a March 5 warning letter, the FDA accused drugmaker Novo Nordisk, the maker of Wegovy and Ozempic, of failing to report some adverse events to the federal government, including suicidal ideation and death
Lifespan Extension Data: What the Published Research Shows Among the most notable published findings on epitalon are the lifespan extension studies conducted in animal models
Some studies link GLP-1 use to an increased risk for ocular diseases such as nonarteritic anterior ischemic optic neuropathy (NAION), diabetic retinopathy, papillitis, and optic nerve disorders